Literature DB >> 18619834

Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer.

Emile Tan1, Nikos Gouvas, R John Nicholls, Paul Ziprin, Evaghelos Xynos, Paris P Tekkis.   

Abstract

INTRODUCTION: The aim of the study was to evaluate the diagnostic precision of serum carcinoembryonic antigen (CEA) in the detection of local or distant recurrence following resectional surgery for colon and rectal cancer.
METHODS: Quantitative meta-analysis was performed on 20 studies, comparing serum CEA with radiological imaging and/or pathology in detecting colorectal cancer (CRC) recurrence in 4285 patients. The cut-off for a 'positive' CEA ranged from 3 to 15 ng/ml between the various studies. Sensitivity, specificity and diagnostic odds ratio (DOR) were calculated for each study. Summary receiver operating characteristic curves (SROC) and sub-group analysis were undertaken.
RESULTS: The overall sensitivity and specificity of CEA for detecting CRC recurrence was 0.64 (95% CI: 0.61-0.67) and 0.90 (95% CI: 0.89-0.91), respectively. The area under the SROC curve was 0.75 (SE=0.04) and the diagnostic odds ratio was 18.44 (95% CI: 11.94-28.49). A CEA cut-off of 5 ng/ml yielded a higher diagnostic odds ratio than a cut-off of 3 ng/ml (15.5 vs. 11.1). Using meta-regression analysis the optimum CEA cut-off point for the best combination of sensitivity and specificity was 2.2 ng/ml. On sub-group analysis high quality studies, and those involving > or =100 patients yielded a marginal improvement in the sensitivity and specificity with minimal change to the SROC.
CONCLUSION: Serum CEA is a test with high specificity but insufficient sensitivity for detecting CRC recurrence in isolation. A cut-off of 2.2 ng/ml may provide an ideal balance of sensitivity and specificity. It may be useful as a first-line surveillance investigation in patients during surgical follow-up based on serial CEA measurements using temporal trends in conjunction with clinical, radiological and/or histological confirmation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18619834     DOI: 10.1016/j.suronc.2008.05.008

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  80 in total

1.  Novel Carcinoembryonic-Antigen-(CEA)-Specific Pretargeting System to Assess Tumor Cell Viability after Irradiation of Colorectal Cancer Cells.

Authors:  Birgit Meller; Margarete Rave-Fränck; Christian Breunig; Markus Schirmer; Manfred Baehre; Roger Nadrowitz; Torsten Liersch; Johannes Meller
Journal:  Strahlenther Onkol       Date:  2011-01-24       Impact factor: 3.621

2.  Detection of relevant colonic neoplasms with PET/CT: promising accuracy with minimal CT dose and a standardised PET cut-off.

Authors:  Wolfgang Luboldt; Teresa Volker; Bärbel Wiedemann; Klaus Zöphel; Ursula Wehrmann; Arne Koch; Todd Toussaint; Nasreddin Abolmaali; Markus Middendorp; Daniela Aust; Jörg Kotzerke; Frank Grünwald; Thomas J Vogl; Hans-Joachim Luboldt
Journal:  Eur Radiol       Date:  2010-05-26       Impact factor: 5.315

3.  Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients.

Authors:  Kristina Schee; Kjersti Flatmark; Ruth Holm; Kjetil Boye; Elisabeth Paus
Journal:  Tumour Biol       Date:  2011-10-18

Review 4.  Do the benefits outweigh the side effects of colorectal cancer surveillance? A systematic review.

Authors:  Knut Magne Augestad; Johnie Rose; Benjamin Crawshaw; Gregory Cooper; Conor Delaney
Journal:  World J Gastrointest Oncol       Date:  2014-05-15

5.  Plasma markers for identifying patients with metastatic melanoma.

Authors:  Harriet M Kluger; Kathleen Hoyt; Antonella Bacchiocchi; Tina Mayer; Jonathan Kirsch; Yuval Kluger; Mario Sznol; Stephan Ariyan; Annette Molinaro; Ruth Halaban
Journal:  Clin Cancer Res       Date:  2011-04-12       Impact factor: 12.531

6.  Survival Outcomes in Asymptomatic Patients With Normal Conventional Imaging but Raised Carcinoembryonic Antigen Levels in Colorectal Cancer Following Positron Emission Tomography-Computed Tomography Imaging.

Authors:  Khurum Khan; Avani Athauda; Katharine Aitken; David Cunningham; David Watkins; Naureen Starling; Gary J Cook; Eleftheria Kalaitzaki; Ian Chau; Sheela Rao
Journal:  Oncologist       Date:  2016-10-14

7.  Evaluation of recurrent disease in the re-staging of colorectal cancer by 18F-FDG PET/CT: Use of CEA and CA 19-9 in patient selection.

Authors:  Agostino Chiaravalloti; Alessandro Fiorentini; Erika Palombo; Davide Rinino; Annamaria Lacanfora; Roberta Danieli; Carmen Di Russo; Daniele Di Biagio; Ettore Squillaci; Orazio Schillaci
Journal:  Oncol Lett       Date:  2016-09-15       Impact factor: 2.967

Review 8.  Early detection of colorectal cancer: from conventional methods to novel biomarkers.

Authors:  Nasimeh Vatandoost; Jahanafrooz Ghanbari; Mahboobeh Mojaver; Amir Avan; Majid Ghayour-Mobarhan; Reza Nedaeinia; Rasoul Salehi
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-17       Impact factor: 4.553

9.  Selective Use of (18)F-Fluorodeoxyglucose-Positron Emission Tomography and Computed Tomography in the Management of Metastatic Disease from Colorectal Cancer: Results from a regional centre.

Authors:  Sadaf Jafferbhoy; Adam Chambers; James Mander; Hugh Paterson
Journal:  Sultan Qaboos Univ Med J       Date:  2015-01-21

Review 10.  Oncolytic measles virus strains as novel anticancer agents.

Authors:  Pavlos Msaouel; Mateusz Opyrchal; Evidio Domingo Musibay; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2013-01-06       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.